Table 4. Therapeutic options for treating latent tuberculosis infection.
| Drugs | Duration | Interval | HIV classification (-) | HIV classification (+) |
|---|---|---|---|---|
| Isoniazid | 9 months | Daily | A (II) | A (II) |
| Isoniazid | 6 months | Daily | B (I) | C (I) |
| Rifampicin + Isoniazid | 3 months | Daily | A (II) | A (II) |
| Rifampicin | 4 months | Daily | B (II) | B (III) |
Note. Weight of recommendation: A: preferable; B: acceptable alternative; C: only use when A and B are not possible. Quality of evidence: I: evidence from random clinical assays; II: evidence from non-random clinical assays. III: expert opinion. HIV: human immunodeficiency virus.